Summary:
- Arrowhead Pharmaceuticals presented Phase 3 clinical trial data (SHASTA-3 and SHASTA-4) for plozasiran, an investigational RNA interference (RNAi) therapeutic targeting APOC3.
- The study demonstrated that plozasiran significantly reduced triglyceride levels and, notably, decreased the incidence of adjudicated acute pancreatitis events in patients suffering from severe hypertriglyceridemia.